Effect of second-generation sulfonylureas on survival in patients with diabetes mellitus after myocardial infarction

Mayo Clinic Proceedings

Volumn 84, Issue 1, 2009, Pages 28-33

  Arruda Olson, Adelaide M ^a   Patch III, Richard K ^a   Leibson, Cynthia L ^a   Vella, Adrian ^a   Frye, Robert L ^a   Weston, Susan A ^a   Killian, Jill M ^a   Roger, Véronique L ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; SULFONYLUREA; SULFONYLUREA DERIVATIVE;

AGED; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; REVASCULARIZATION; RISK ASSESSMENT; SURVIVAL RATE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; FOLLOW UP; HEALTH SURVEY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNITED STATES;

AGED; CONFIDENCE INTERVALS; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MINNESOTA; MYOCARDIAL INFARCTION; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 58749083391     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/84.1.28     Document Type: Article

References (34)

1. Hurst RT, Lee RW. Increased incidence of coronary atherosclerosis in type 2 diabetes mellitus: mechanisms and management. Ann Intern Med. 2003;139(10):824-834.
2. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA. 1999;281(14):1291-1297.
3. Orlander PR, Goff DC, Morrissey M, et al. The relation of diabetes to the severity of acute myocardial infarction and post-myocardial infarction survival in Mexican-Americans and non-Hispanic whites: the Corpus Christi Heart Project. Diabetes. 1994;43(7):897-902.
4. Gandhi GY, Roger VL, Bailey KR, Palumbo PJ, Ransom JE, Leibson CL. Temporal trends in prevalence of diabetes mellitus in a population-based cohort of incident myocardial infarction and impact of diabetes on survival. Mayo Clin Proc. 2006;81(8):1034-1040.
5. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. American Diabetes Association: clinical practice recommendations 2002. Diabetes Care. 2002;25(suppl 1):S1-S147.
6. Brady PA, Terzic A. The sulfonylurea controversy: more questions from the heart. J Am Coll Cardiol. 1998;31(5):950-956.
7. US Food and Drug Administration. Approved Drug Products With Therapeutic Equivalence Evaluations: Orange Book. 26th ed. Rockville, MD: US Food and Drug Administration; 2006:1022.
8. Panten U, Schwanstecher M, Schwanstecher C. Sulfonylurea receptors and mechanism of sulfonylurea action. Exp Clin Endocrinol Diabetes. 1996;104(1):1-9.
9. + channel blocker. Circulation. 1994;90(2):700-705.
10. Cleveland JC Jr, Meldrum DR, Cain BS, Banerjee A, Harken AH. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium: two paradoxes revisited. Circulation. 1997;96(1):29-32.
11. Meier JJ, Gallwitz B, Schmidt WE, Mügge A, Nauck MA. Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Heart. 2004;90(1):9-12. http://www.pubmedcentral.nih.gov/articlerender. fcgi?artid=1768037. Accessed November 24, 2008.
12. Brady PA, Jovanovic A. The sulfonylurea controversy: much ado about nothing or cause for concern [editorial]? J Am Coll Cardiol. 2003;42(6):1022-1025.
13. Schwartz TB, Meinert CL. The UGDP controversy: thirty-four years of contentious ambiguity laid to rest. Perspect Biol Med. 2004;47(4):564-574.
14. Melton LJ III. History of the Rochester Epidemiology Project. Mayo Clin Proc. 1996;71(3):266-274.
15. White AD, Folsom AR, Chambless LE, et al. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience. J Clin Epidemiol. 1996;49(2):223-233.
16. Roger VL, Jacobsen SJ, Weston SA, et al. Trends in the incidence and survival of patients with hospitalized myocardial infarction, Olmsted County, Minnesota, 1979 to 1994. Ann Intern Med. 2002;136(5):341-348.
17. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979;28(12):1039-1057.
18. Prineas RJ, Crow RS, Blackburn H. The Minnesota Code Manual of Electrocardiographic Findings: Standards and Procedures for Measurement and Classification. Boston, MA: Wright-PSG; 1982.
19. Hellermann JP, Reeder GS, Jacobsen SJ, Weston SA, Killian JM, Roger VL. Longitudinal trends in the severity of acute myocardial infarction: a population study in Olmsted County, Minnesota. Am J Epidemiol. 2002;156(3):246-253.
20. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26(11):3160-3167.
21. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes, II: mortality results. Diabetes. 1970;19(suppl 2):789-830.
22. Gross GJ, Auchampach JA. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res. 1992;70(2):223-233.
23. Toombs CF, Moore TL, Shebuski RJ. Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamide. Cardiovasc Res. 1993;27(4):617-622.
24. Engler RL, Yellon DM. Sulfonylurea KATP blockade in type II diabetes and preconditioning in cardiovascular disease: time for reconsideration. Circulation. 1996;94(9):2297-2301.
25. Deutsch E, Berger M, Kussmaul WG, Hirshfeld JW Jr, Herrmann HC, Laskey WK. Adaptation to ischemia during percutaneous transluminal coronary angioplasty: clinical, hemodynamic, and metabolic features. Circulation. 1990;82(6):2044-2051.
26. Cribier A, Korsatz L, Koning R, et al. Improved myocardial ischemic response and enhanced collateral circulation with long repetitive coronary occlusion during angioplasty: a prospective study. J Am Coll Cardiol. 1992;20(3):578-586.
27. Perrault LP, Menasché P, Bel A, et al. Ischemic preconditioning in cardiac surgery: a word of caution. J Thorac Cardiovasc Surg. 1996;112(5):1378-1386.
28. Barbash GI, White HD, Modan M, Van de Werf F. Antecedent angina pectoris predicts worse outcome after myocardial infarction in patients receiving thrombolytic therapy: experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. J Am Coll Cardiol. 1992;20(1):36-41.
29. Behar S, Reicher-Reiss H, Abinader E, et al. The prognostic significance of angina pectoris preceding the occurrence of a first acute myocardial infarction in 4166 consecutive hospitalized patients. Am Heart J. 1992;123(6):1481-1486.
30. Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR Jr. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol. 1999;33(1):119-124.
31. Johnsen SP, Monster TB, Olsen ML, et al. Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs. Am J Ther. 2006;13(2):134-140.
32. Jollis JG, Simpson RJ Jr, Cascio WE, Chowdhury MK, Crouse JR III, Smith SC Jr. Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction. Am Heart J. 1999;138(5, pt 1):S376-S380.
33. Klamann A, Sarfert P, Launhardt V, Schulte G, Schmiegel WH, Nauck MA. Myocardial infarction in diabetic vs non-diabetic subjects: survival and infarct size following therapy with sulfonylureas (glibenclamide). Eur Heart J. 2000;21(3):220-229.
34. Horsdal HT, Johnsen SP, Søndergaard F, Rungby J. Type of pre-admission glucose-lowering treatment and prognosis among patients hospitalised with myocardial infarction: a nationwide follow-up study. Diabetologia. 2008 Apr;51(4):567-574. Epub 2008 Feb 19.